Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1340-1347

  Cope, Keary ^a   Risby, Terence ^a   Diehl, Anna Mae ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b 912 Ross Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIINFECTIVE AGENT; NEOMYCIN;

AGING; ANIMAL; ARTICLE; BODY WEIGHT; BREATH ANALYSIS; C57BL MOUSE; CIRCADIAN RHYTHM; DIGESTIVE SYSTEM; DRUG ANTAGONISM; FATTY LIVER; GENETICS; MALE; METABOLISM; MOUSE; OBESITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; REFERENCE VALUE;

ADMINISTRATION, ORAL; AGING; ANIMALS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; BREATH TESTS; CIRCADIAN RHYTHM; DIGESTIVE SYSTEM; ETHANOL; FATTY LIVER; MALE; MICE; MICE, INBRED C57BL; NEOMYCIN; OBESITY; REFERENCE VALUES;

EID: 0034320252     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19267     Document Type: Article

References (57)

1. Matteoni C, Younossi ZM, McCullough A. Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology 1999;116:1413-1419.
2. Caldwell SH, Oelsner DH, lezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664669.
3. Giraud NS, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25:108-111.
4. Sheth SG, Gordon FD, Chopar S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.
5. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:342-348.
6. Nosova T, Jokelainen K, Kaihovaara P, Jousimies-somer H, Siitonen A, Heine R, Salaspuro M. Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. Alcohol Alcohol 1996;31:555564.
7. Baraona E, Julkunen R, Tannenbaum L, Lieber CS. Role of intestinal bacterial overgrowth in ethanol production and metabolism in rats. Gastroenterology 1986;90:103-110.
8. Mezey E, Imbembo AL, Potter JJ, Rent KC, Lombardo R, Holt PR. Endogenous ethanol production and hepatic disease following jejunoileal bypass for morbid obesity. Am J Clin Nutr 1975;28: 1277-1283.
9. Lieber C. Hepatic, metabolic and toxic effect of ethanol. 1991 update. Alcohol Clin Exp Res 1991;15:573-592.
10. Crowell MD, Cheskin U, Musial F. Prevalence of gastrointestinal symptoms in obese and normal weight binge eaters. Am J Gastroenterol 1994;89:387-391.
11. Weiner P, Shlum H, Ganam R, Plavnick L. Colonie pseudo-obstruction: a late complication of jejunoileal bypass. Isr J Med Sei 1984;20:405-406.
12. O'Malley KJ, Rechner SM, Kapoor A, Rhodes RA, Modlin CS, Goldfarb DA, Novick AC. Acute colonie pseudo-obstruction (Ogilvie's syndrome) after renal transplantation. Am J Surg 1999;177: 492-495.
13. Niederau C, Meereis-Schwanke K, Klonowski-Stumpe H, Herberg L. CCK-resistance in Zucker obese versus lean rats. Regul Pept 1997;70:97-104.
14. Fink H, Rex A, Voits M, Voigt JP. Major biological actions of CCK-a critical evaluation of research findings. Exp Brain Res 1998:123:77-83.
15. Lieverse RJ, Masclee AA, Jansen JB, Lam WF, Lamers CB. Obese women are less sensitive for the satiety effects of bombesin than lean women. Eur J Clin Nutr 1998;52:207s-212s.
16. Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm Metab Res 1996;28:619-632.
17. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis. Proc Natl Acad Sei U S A 1997; 94:2557-2562.
18. RisbyT, Jiang L, Stoll S, Ingram D, Spangler E, Heim J, Cutler R, Roth GS, Rifkind JM. Breath ethane as a marker of reactive oxygen species during manipulation of diet and oxygen tension in rats. J Appl Physiol 1999;86:617-622.
19. RisbyTH, SehnertSS. Clinical application of breath biomarkersof oxidative stress status. rree Radical Biol Med 1999:27:1118211192.
20. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury n rats following long-term exposure to ethanol. Gastroenteroloy 1995:108:218-224.
21. Samazasinghe D, Tasman-Jones C. The clinical associations with hepatic steatosis: a retrospective study. N Z Med J 1992;105: 57-58.
22. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic ramaler. Hepatology 1995;21:1742-1744.
23. Pelleymounter MA, Culhsn MF, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995:269:540-543.
24. Breslow MJ, Min-Lee K, Brown DR, Chacko VP, Palmer D, Berkowitz DE. Effect of leptin deficiency on metabolic rate in ob/ob mice. Am J Physiol 1999;276:E443-E449.
25. Hwa JJ, Ghibaudi L, Conpton D, Fawzi AB, Strader CD. Intracerebroventricular injection of leptin increases thermogenesis and moilizes fat metabolism in ob/ob mice. Horm Metab Res 1996; 28:659-663.
26. Refinetti R. Effect of amt lent temperature on respiratory quotient of lean and obese Zucker rats. Am J Physiol 1989;256:R236-R239.
27. Williamson DF, Kahn Ho, Byers T. The 10-y incidence of obesity and major weight gain i i black and white US women aged 30-55 y. Am J Clin Nutr 1991 53(suppl):1515S-1518S.
28. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119:655-660.
29. Rosenbaum M, Leibel FiL, Hirsch J. Obesity. N Engl J Med 1997; 337:396-407.
30. Dubowski KM, Essary NA. Measurement of low breath-alcohol concentrations: labora'.ory studies and field experience. J Anal Toxicol 1999;23:386-395.
31. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster Ml, Thurman RG. Essential role of tumor necrosis factor alpha in alcohol-induced liver in ury in mice. Gastroenterology 1999;117: 942-952.
32. Leung FW, Drenick EJ, Stanley TM. Intestinal bypass complications involving the excluded small bowel segment. Am J Gastroenterol 1982;77:67-72.
33. Jorizzo JL, Apisarntha wax P, Subrt P, Hebert AA, Henry JC, Raimer SS, Dinehart JM, Reinarz JA. Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrom. Arch Intern Med 1983:143:457-461.
34. Drenick EJ, Roslyn JJ. Cure of arthritis-dermatitis syndrome due to intestinal bypass by resection of nonfunction segment of blind loop. Dig Dis Sei 1990;35:656-660.
35. Mayeux PR. Patnobiology of lipopolysaccharide. J Toxicol Environ Health 1997;51:415-435.
36. Nanji AA, Khettry U, sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver disease. Proc Soc Exp Biol Med 1994;205:243-247.
37. Bjarnason I, Waard K, Deters TJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984;1:179-182.
38. Nolan JP. Intestinal endotoxins as mediators of hepatic injury-an idea whose time has come again. Hepatology 1989:8:252-256.
39. Fox ES, Broitman AS, Thomas P. Bacterial endotoxins and the liver. Lab Invest 199C;63:733-741.
40. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990; 14-.255-259.
41. Bird GLA, Sheron N, Goka AKJ, Alexander GL, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920.
42. Khoruts A, Stahnke L, McClain CJ, Logan G, Alien Jl. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991;13:267-276.
43. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: réévaluation with an improved chromogenic assay. Hepatology 1991;12:162-169.
44. Hill D, Marsano L, Cohen D, Alien J, Shedlosfsky S, McClain CJ. Increased plasma interleukin-6 activity in alcoholic hepatitis. J Lab Clin Med 1992;119:507-512.
45. Earnest DL, Evril ER, Jolley C, Martinez F. Ethanol and dietinduced alterations in Kupffer cell function. Alcohol Alcohol 1993;28:73-83.
46. Kamimura S, Tsukamoto H. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. Hepatology 1995; 22:1304-1309.
47. Nanji AA, Zakim D, Rahemtulla A, DalyT, Miao L, Zhao S, Khwaja S, Tahan SR, Dannenberg AJ. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and TNF-alpha and reverse fibrosis in experimental alcoholic liver disease. Hepatology 1997:26:1538-1545.
48. limuro Y, Gallucci RM, Luster Ml, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa attenuates hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26:1530-1537.
49. Kern PA, Saghizaheh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-2119.
50. Hotamisligil GS, Peraldi SP, Budavari A, Ellis R, White MF, Spiegelman BA. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-668.
51. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin-resistance in mice lacking TNF alpha function. Nature 1997;389:610-614.
52. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchiondo N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
53. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73-76.
54. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
55. Moller DE, Flier JS. Insulin resistance. Mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-948.
56. De Fronzo RA, Ferranini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991:14:173-194.
57. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149.